Secretory Transactivating Transcription-apoptin fusion protein induces apoptosis in hepatocellular carcinoma HepG2 cells

World Journal of Gastroenterology

Volumn 14, Issue 23, 2008, Pages 3642-3649

  Han, Su Xia ^a,b   Ma, Jin Lu ^b   Lv, Yi ^b   Huang, Chen ^b   Liang, Hai Hua ^a   Duan, Kang Min ^a  

^a NORTHWEST UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Apoptin; Apoptosis; Hepatoma; Human immunodeficiency virus transactivating; Secretory; transcription protein

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; HYBRID PROTEIN; LIPOCORTIN 5; SECRETORY TRANSACTIVATING TRANSCRIPTION APOPTIN; SIGNAL PEPTIDE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BYSTANDER EFFECT; CANCER CELL CULTURE; CELL COMPARTMENTALIZATION; CELL DEATH; CELL SPECIFICITY; CELL VIABILITY; CONTROLLED STUDY; DNA DETERMINATION; DNA SEQUENCE; DRUG DESIGN; DRUG TARGETING; ENDOTHELIUM CELL; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CELL; PROTEIN EXPRESSION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UMBILICAL VEIN;

EID: 54349111652     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.3642     Document Type: Article

References (30)

1. Noteborn MH. Chicken anemia virus induced apoptosis: underlying molecular mechanisms. Vet Microbiol 2004; 98: 89-94
2. Olijslagers SJ, Zhang YH, Backendorf C, Noteborn MH. Additive cytotoxic effect of apoptin and chemotherapentic agents paclitaxel and etoposide on human tumour cells. Basic Clin Pharmacol Toxicol 200; 100: 127-131
3. Janssen K, Hofmann TG, Jans DA, Hay RT, Schulze-Osthoff K, Fischer U. Apoptin is modified by SUMO conjugation and tarcreted to promyelocytic leukemia protein nuclear bodies. Oncogene 2007; 26: 1557-1566
4. Burek M, Maddika S, Burek CJ, Daniel PT, Schulze-Osthoff K. Los M. Apoptin-induced cell death is modulated by Bcl-2 family members and is Apaf-1 dependent. Oncogene 2006; 25: 2213-2222
5. Russo A, Terrasi M, Agnese V, Santini D, Bazan V. Apoptosis: a relevant tool for anticancer therapy. Ann Oncol 2006; 17 Suppl 7: vii115-vii123
6. Liu X, Elojeimy S, El-Zawahry AM, Holman DH, Bielawska A, Bielawski J, Rubinchik S, Guo GW, Don JY, Keane T, Hannun YA, Tavassoli M, Norris JS. Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer. Mol Ther 2006; 14: 637-646
7. Maddika S, Mendoza FJ, Hauff K, Zamzow CR, Paranjothy T, Los M. Cancer-selective therapy of the future: apoptin and its mechanism of action. Cancer Biol Ther 2006; 5: 10-19
8. Peng DJ, Sun J, Wang YZ, Tian J, Zhang YH, Noteborn MH, Qu S. Inhibition of hepatocarcinoma by systemic delivery of Apoptin gene via the hepatic asialoglycoprotein receptor. Cancer Gene Ther 2007; 14: 66-73
9. Wang QM, Fan GC, Chen JZ, Chen HP, He FC. A putative NES mediates cytoplasmic localization of Apoptin in normal cells. Acta Biochim Biophys Sin (Shanghai) 2004; 36: 817-823
10. Hashida H, Miyamoto M, Cho Y, Hida Y, Kato K, Kurokawa T, Okushiba S, Kondo S, Dosaka-Akita H, Katoh H. Fusion of HIV-1 Tat protein transduction domain to poly-lysine as a now DNA delivery tool. Br J Cancer 2004; 90: 1252-1258
11. Kubo E, Fatma N, Akagi Y, Beier DR, Singh SP, Singh DP. TAT-mediated PRDX6 protein transduction protects against eye lens epithelial cell death and delays lens opacity. Am J Physiol Cell Physiol 2008; 294: C842-C855
12. Song HY, Lee JA, Ju SM, Yoo KY, Won MH, Kwon HJ, Eum WS, Jang SH, Choi SY, Park J. Topical transduction of superoxide dismutasee mediated by HIV-1 Tat protein transduction domain ameliorates 12-0-tetradecanoylphorbol-13-acetate (TPA)-induced inflammation in mice. Biochem Pharmacol 2008; 75: 1348-1357.
13. Ziegler A, Seelig J. interaction of the protein transduction domain of HIV-1 TAT with heparan sulfate: binding mechanism and thermodynamic parameters. Biophys J 2004; 86; 254-263
14. Guelen L, Paterson H, Gaken J, Meyers M, Farzaneh F, Tavassoli M. TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells. Oncogene 2004; 23: 1153-1165
15. Barash S, Wang W, Shi Y. Human secretory signal peptide description by hidden Markov model and generation of a strong artificial signal peptide for secreted protein expression. Biochem Biophys Res Commun, 2002; 294: 835-842
16. Sun GJ, Tong X, Sun ZX, Gene clone and activity assay of apoptin. Junshi Yixue Kexueyuun Yuankun 2001; 2: 85-87
17. Hayon T, Dvilansky A, Shpilberg O, Nathan I. Appraisal of the MTT-based assay as a useful tool for predicting drug chemosensitivity in leukemia. Leuk Lymphoma 2003; 44: 1957-1962
18. Kubota T. (Cancer chemosensitivity test-from laboratory to clinic) Hum Cell 1995; 8: 189-194
19. Lee YH, Cheng CM, Chang YF, Wang TY, Yuo CY. Apoptin T108 phosphorylation is not required for its tumor-specific nuclear localization but partially affects its apoptotic activity. Biochem Biophys Res Commun 2007; 354: 391-395
20. Olijslagers SJ, Zhang YH, Backendorf C, Noteborn MH. Additive cytotoxic effect of apoptin and chemotherapeutic agents paclitaxel and etoposide on human tumour cells. Basic Clin Pharmacol Toxicol 2007; 100: 127-131
21. Danen-Van Oorschot AA, Zhang YH, Leliveld SK, Kohn JL, Seelen MC, Bolk MW, Van Zon A, Erkeland SJ, Abrahams JP, Mumberg D, Noteborn MH. Importance of nuclear localization of apoptin for tumor-specific induction of apoptosis. J Biol Chem 2003; 278: 27729-27736
22. Alvisi G, Poon IK, Jans DA. Tumor-specific nuclear targeting: promises for anti-cancer therapy? Drug Resist Updat 2006; 9: 40-50
23. Poon IK Oro C, Dias MM, Zhang J, Jans DA. Apoptin nuclear accumulation is modulated bv a CRM1-recognized nuclear export signal that is active in normal but not in tumor cells. Cancer Res 2005; 65: 7059-7064
24. He X, Zhang Q, Liu Y, He P. Apoptin Induces Chromatin Condensation in Normal Cells. Virus Genes 2005; 31: 49-55
25. Gdynia G, Lehmann-Koch J, Sieber S, Tagscherer KF, Fassl A, Zentgraf H, Matsuzawa S, Reed JC, Roth W. BLOC1S2 interacts with the HIPPI protein and sensitizes NCH89 glioblastoma cells to apoptosis. Apoptosis 2008; 13: 437-447
26. Maddika S, Wiechec, E, Ande SR, Poon TK, Fischer U, Wesselborg, S, Jans DA, Schulze-Osthoff K, Los M. Interaction with P13-kinase contributes to the cytotoxic activity of apoplin. Oncogene 2008; 27: 3060-3065
27. Maddika S, Bay GH, Kroczak TJ, Ande SR, Maddika S, Wiechec F, Gibson SB, Los M. Akt is transferred to the nucleus of cells treated with apoptin, and it participates in apoptin-induced cell death. Cell Prolif 2007; 40: 835-848
28. Backendorf C, Visser AE, de Boer AG, Zimmerman R, Visser M, Voskamp P, Zhang YH, Noteborn M. Apoptin: therapeutic potential of an early sensor of carcinogenic transformation. Annu Rev Pharmacol Toxicol 2008; 48; 143-169
29. Schoop RA, Kooistra K, Baatenburg De Jong RJ, Noteborn MH. Bc1-xL inhibits p53- but not apoptin-induced apoptosis in head and neck squamous cell carcinoma cell line. Int J Cancer 2004; 109: 38-42
30. Maddika S, Mendoza FJ Hauff K, Zamzow CR, Paranjothy T, Los M. Cancer-selective therapy of the future: apoptin and its mechanism of action. Cancer Biol Ther 2006; 5: 10-19